Skip Navigation


European Heart Journal Advance Access originally published online on September 21, 2009
European Heart Journal 2009 30(21):2554-2555; doi:10.1093/eurheartj/ehp384
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/21/2554    most recent
ehp384v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Camm, A. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camm, A. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

The RE-LY study: Randomized Evaluation of Long-term anticoagulant therapY: dabigatran vs. warfarin

A. John Camm*

St George's University of London, London, UK

* Corresponding author. Tel: +44 208 725 3554, Fax: +44 208 767 7141, Email: jcamm@sgul.ac.uk

The first 10% of the full text of this article appears below.

This commentary refers to ‘Dabigatran versus warfarin in patients with atrial fibrillation’{dagger}, by S.J. Connolly, published in the New England Journal of Medicine, 2009; 361:1139–1151

Atrial fibrillation is an increasingly common arrhythmia, now said to stand at epidemic proportion in Western societies: >2.3 million people in the USA and >4.5 million people in Western Europe. It is an expression of underlying heart disease and a threat to life and living. In particular it is associated with 4.5-fold risk of stroke,1 predominantly ischaemic in nature, largely due to embolization of a left atrial clot. Over the last several decades a formidable evidence base has been developed for the use of anticoagulant therapy,2 mostly warfarin/coumadin, and antiplatelet therapy, predominantly aspirin and more recently clopidogrel plus aspirin.3

Although warfarin is undoubtedly an effective anticoagulant therapy, its application is associated with a highly . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


E-letters:

Read all E-letters

Dabigatran versus warfarin: a clear result?
A. John Camm, et al.
European Heart Journal, 26 Nov 2009 [Full text]
RE-LY study (dabigatran vs. warfarin in atrial fibrillation) – a call for caution
Christian A Gericke, et al.
European Heart Journal, 26 Nov 2009 [Full text]